Your browser doesn't support javascript.
loading
Pan-cancer analysis of pre-diagnostic blood metabolite concentrations in the European Prospective Investigation into Cancer and Nutrition.
Breeur, Marie; Ferrari, Pietro; Dossus, Laure; Jenab, Mazda; Johansson, Mattias; Rinaldi, Sabina; Travis, Ruth C; His, Mathilde; Key, Tim J; Schmidt, Julie A; Overvad, Kim; Tjønneland, Anne; Kyrø, Cecilie; Rothwell, Joseph A; Laouali, Nasser; Severi, Gianluca; Kaaks, Rudolf; Katzke, Verena; Schulze, Matthias B; Eichelmann, Fabian; Palli, Domenico; Grioni, Sara; Panico, Salvatore; Tumino, Rosario; Sacerdote, Carlotta; Bueno-de-Mesquita, Bas; Olsen, Karina Standahl; Sandanger, Torkjel Manning; Nøst, Therese Haugdahl; Quirós, J Ramón; Bonet, Catalina; Barranco, Miguel Rodríguez; Chirlaque, María-Dolores; Ardanaz, Eva; Sandsveden, Malte; Manjer, Jonas; Vidman, Linda; Rentoft, Matilda; Muller, David; Tsilidis, Kostas; Heath, Alicia K; Keun, Hector; Adamski, Jerzy; Keski-Rahkonen, Pekka; Scalbert, Augustin; Gunter, Marc J; Viallon, Vivian.
Affiliation
  • Breeur M; Nutrition and Metabolism Branch, International Agency for Research on Cancer, NME Branch, 69372 CEDEX 08, Lyon, France.
  • Ferrari P; Nutrition and Metabolism Branch, International Agency for Research on Cancer, NME Branch, 69372 CEDEX 08, Lyon, France.
  • Dossus L; Nutrition and Metabolism Branch, International Agency for Research on Cancer, NME Branch, 69372 CEDEX 08, Lyon, France.
  • Jenab M; Nutrition and Metabolism Branch, International Agency for Research on Cancer, NME Branch, 69372 CEDEX 08, Lyon, France.
  • Johansson M; Genetics Branch, International Agency for Research on Cancer, 69372 CEDEX 08, Lyon, France.
  • Rinaldi S; Nutrition and Metabolism Branch, International Agency for Research on Cancer, NME Branch, 69372 CEDEX 08, Lyon, France.
  • Travis RC; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
  • His M; Nutrition and Metabolism Branch, International Agency for Research on Cancer, NME Branch, 69372 CEDEX 08, Lyon, France.
  • Key TJ; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
  • Schmidt JA; Cancer Epidemiology Unit, Nuffield Department of Population Health, University of Oxford, Oxford, OX3 7LF, UK.
  • Overvad K; Department of Clinical Epidemiology, Department of Clinical Medicine, Aarhus University Hospital and Aarhus University, DK-8200, Aarhus N, Denmark.
  • Tjønneland A; Department of Public Health, Aarhus University, DK-8000, Aarhus C, Denmark.
  • Kyrø C; Danish Cancer Society Research Center Diet, Genes and Environment Nutrition and Biomarkers, DK-2100, Copenhagen, Denmark.
  • Rothwell JA; Danish Cancer Society Research Center Diet, Genes and Environment Nutrition and Biomarkers, DK-2100, Copenhagen, Denmark.
  • Laouali N; Université Paris-Saclay, UVSQ, Inserm, CESP U1018, "Exposome and Heredity" team, Gustave Roussy, 94800, Villejuif, France.
  • Severi G; Université Paris-Saclay, UVSQ, Inserm, CESP U1018, "Exposome and Heredity" team, Gustave Roussy, 94800, Villejuif, France.
  • Kaaks R; Université Paris-Saclay, UVSQ, Inserm, CESP U1018, "Exposome and Heredity" team, Gustave Roussy, 94800, Villejuif, France.
  • Katzke V; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Schulze MB; Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), 69120, Heidelberg, Germany.
  • Eichelmann F; Department of Molecular Epidemiology, German Institute of Human Nutrition, 14558, Nuthetal, Germany.
  • Palli D; Department of Molecular Epidemiology, German Institute of Human Nutrition, 14558, Nuthetal, Germany.
  • Grioni S; German Center for Diabetes Research (DZD), 85764, Neuherberg, Germany.
  • Panico S; Institute of Cancer Research, Prevention and Clinical Network (ISPRO), 50139, Florence, Italy.
  • Tumino R; Epidemiology and Prevention Unit, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, 20133, Milan, Italy.
  • Sacerdote C; Dipartimento di Medicina Clinica e Chirurgia, Federico II University, 80131, Naples, Italy.
  • Bueno-de-Mesquita B; Hyblean Association for Epidemiological Research, AIRE-ONLUS, 97100, Ragusa, Italy.
  • Olsen KS; Unit of Cancer Epidemiology Città della Salute e della Scienza University-Hospital, 10126, Turin, Italy.
  • Sandanger TM; Centre for Nutrition, Prevention and Health Services, National Institute for Public Health and the Environment (RIVM), PO Box 1, 3720, BA, Bilthoven, The Netherlands.
  • Nøst TH; Department of Community Medicine, UiT The Arctic University of Norway, N-9037, Tromsø, Norway.
  • Quirós JR; Department of Community Medicine, UiT The Arctic University of Norway, N-9037, Tromsø, Norway.
  • Bonet C; Department of Community Medicine, UiT The Arctic University of Norway, N-9037, Tromsø, Norway.
  • Barranco MR; Public Health Directorate, 33006, Oviedo, Asturias, Spain.
  • Chirlaque MD; Unit of Nutrition and Cancer, Cancer Epidemiology Research Program, Catalan Institute of Oncology (ICO), Bellvitge Biomedical Research Institute (IDIBELL), L'Hospitalet de Llobregat, 08908, Barcelona, Spain.
  • Ardanaz E; Escuela Andaluza de Salud Pública (EASP), 18011, Granada, Spain.
  • Sandsveden M; Instituto de Investigación Biosanitaria ibs. GRANADA, 18012, Granada, Spain.
  • Manjer J; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
  • Vidman L; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
  • Rentoft M; Department of Epidemiology, Regional Health Council, IMIB-Arrixaca, Murcia University, 30003, Murcia, Spain.
  • Muller D; Centro de Investigación Biomédica en Red de Epidemiología y Salud Pública (CIBERESP), 28029, Madrid, Spain.
  • Tsilidis K; Navarra Public Health Institute, 31003, Pamplona, Spain.
  • Heath AK; IdiSNA, Navarra Institute for Health Research, 31008, Pamplona, Spain.
  • Keun H; Department of Clinical Sciences Malmö Lund University, SE-214 28, Malmö, Sweden.
  • Adamski J; Departement of Surgery, Skåne University Hospital Malmö, Lund University, SE-214 28, Malmö, Sweden.
  • Keski-Rahkonen P; Department of Radiation Sciences, Oncology Umeå University, SE-901 87, Umeå, Sweden.
  • Scalbert A; Department of Radiation Sciences, Oncology Umeå University, SE-901 87, Umeå, Sweden.
  • Gunter MJ; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK.
  • Viallon V; Department of Epidemiology and Biostatistics, School of Public Health, Imperial College London, London, W2 1PG, UK.
BMC Med ; 20(1): 351, 2022 10 19.
Article in En | MEDLINE | ID: mdl-36258205
ABSTRACT

BACKGROUND:

Epidemiological studies of associations between metabolites and cancer risk have typically focused on specific cancer types separately. Here, we designed a multivariate pan-cancer analysis to identify metabolites potentially associated with multiple cancer types, while also allowing the investigation of cancer type-specific associations.

METHODS:

We analysed targeted metabolomics data available for 5828 matched case-control pairs from cancer-specific case-control studies on breast, colorectal, endometrial, gallbladder, kidney, localized and advanced prostate cancer, and hepatocellular carcinoma nested within the European Prospective Investigation into Cancer and Nutrition (EPIC) cohort. From pre-diagnostic blood levels of an initial set of 117 metabolites, 33 cluster representatives of strongly correlated metabolites and 17 single metabolites were derived by hierarchical clustering. The mutually adjusted associations of the resulting 50 metabolites with cancer risk were examined in penalized conditional logistic regression models adjusted for body mass index, using the data-shared lasso penalty.

RESULTS:

Out of the 50 studied metabolites, (i) six were inversely associated with the risk of most cancer types glutamine, butyrylcarnitine, lysophosphatidylcholine a C182, and three clusters of phosphatidylcholines (PCs); (ii) three were positively associated with most cancer types proline, decanoylcarnitine, and one cluster of PCs; and (iii) 10 were specifically associated with particular cancer types, including histidine that was inversely associated with colorectal cancer risk and one cluster of sphingomyelins that was inversely associated with risk of hepatocellular carcinoma and positively with endometrial cancer risk.

CONCLUSIONS:

These results could provide novel insights for the identification of pathways for cancer development, in particular those shared across different cancer types.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: BMC Med Journal subject: MEDICINA Year: 2022 Document type: Article Affiliation country: France
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Carcinoma, Hepatocellular / Liver Neoplasms Type of study: Diagnostic_studies / Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Humans / Male Language: En Journal: BMC Med Journal subject: MEDICINA Year: 2022 Document type: Article Affiliation country: France